- Report
- December 2024
- 90 Pages
Global
From €2184EUR$2,400USD£1,873GBP
- Clinical Trials
- March 2025
- 60 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- November 2022
- 154 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- February 2022
- 360 Pages
United States
From €3276EUR$3,600USD£2,809GBP
- Report
- March 2021
- 240 Pages
United States
From €2730EUR$3,000USD£2,341GBP
- Report
- June 2021
- 50 Pages
China
From €2366EUR$2,600USD£2,029GBP
- Drug Pipelines
- November 2020
- 78 Pages
Global
From €3185EUR$3,500USD£2,731GBP
- Report
- December 2020
- 60 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Report
- August 2018
- 37 Pages
Global
From €9101EUR$10,000USD£7,802GBP
Daratumumab is a monoclonal antibody used to treat multiple myeloma, a type of cancer that affects the bone marrow. It is also being studied for its potential use in treating other types of cancer, including those of the central nervous system. Daratumumab works by targeting a protein found on the surface of cancer cells, which helps to slow down the growth and spread of the cancer.
In the context of central nervous system drugs, Daratumumab is being studied for its potential to treat glioblastoma, a type of brain cancer. It is also being studied for its potential to treat other types of brain tumors, such as meningiomas and medulloblastomas. Clinical trials are ongoing to evaluate the safety and efficacy of Daratumumab in these types of cancers.
Some companies in the Daratumumab market include Janssen Biotech, Inc., Genmab A/S, and AbbVie, Inc. Show Less Read more
